Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis symptoms during the pollen season preceding the study, confirmed by SPT (prick tests) and/or a positive specific IgE CAP test for birch pollen (class I minimum)~* Positive SPT to Bet v 1 (prick tests), negative SPT to AllerT~Exclusion Criteria:~* received immunotherapy against any allergen within 3 years before the start of the study.~* symptomatic to perennial allergens or active seasonal allergy during the trial.~* non controlled asthma (peak flow lower than 30% of predicted value).~* history of any severe medical condition able to influence the course of the study~* Any confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection and asplenia.~* Subjects under immunosuppressive medication.~* Pregnant or lactating women or women willing or intending to become pregnant during the study.~* Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- AllerT SC (Type: EXPERIMENTAL): AllerT subcutaneous injections
- Placebo SC (Type: PLACEBO_COMPARATOR): placebo subcutaneous injections
- AllerT ID (Type: EXPERIMENTAL): AllerT intra-dermal injections
- Placebo ID (Type: PLACEBO_COMPARATOR): placebo intra-dermal injections

Based on this trial design, predict the completion outcome and termination type (if applicable).